TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients wit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Del Bianco, Paola, Stagni, Camilla, Giunco, Silvia, Fabozzi, Alessio, Elefanti, Lisa, Pellegrini, Stefania, Vecchiato, Antonella, Pigozzo, Jacopo, Zamuner, Carolina, De Rossi, Anita, De Nicolo, Arcangela, Menin, Chiara
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226422/
https://ncbi.nlm.nih.gov/pubmed/32290374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040946
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares